Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.


We recently reported that circulating apolipoprotein AII (apoAII) isoforms apoAII-ATQ/AT (C-terminal truncations of the apoAII homo-dimer) decline significantly in pancreatic cancer and thus might serve as plasma biomarkers for the early detection of this disease. We report here the development of novel enzyme-linked immunosorbent assays (ELISAs) for measurement of apoAII-ATQ/AT and their clinical applicability for early detection of pancreatic cancer. Plasma and serum concentrations of apoAII-ATQ/AT were measured in three independent cohorts, which comprised healthy control subjects and patients with pancreatic cancer and gastroenterologic diseases (n = 1156). These cohorts included 151 cases of stage I/II pancreatic cancer. ApoAII-ATQ/AT not only distinguished the early stages of pancreatic cancer from healthy controls but also identified patients at high risk for pancreatic malignancy. AUC values of apoAII-ATQ/AT to detect early stage pancreatic cancer were higher than those of CA19-9 in all independent cohorts. ApoAII-ATQ/AT is a potential biomarker for screening patients for the early stage of pancreatic cancer and identifying patients at risk for pancreatic malignancy (161 words).


The following biomarkers make reference to this publication:


One protocol is associated with this publication:

  • Honda K
  • Huang Y
  • Ioka T
  • Jung G
  • Kamita M
  • Kobayashi M
  • Kosuge T
  • Marsh T
  • Miura N
  • Nakamori S
  • Okusaka T
  • Rinaudo JA
  • Sakamoto T
  • Sanada M
  • Sasajima Y
  • Sata N
  • Shimahara M
  • Shoji H
  • Srivastava S
  • Tsuchida A
  • Ueno T
  • Yamada T
  • Yasunami Y
PubMed ID
Appears In
Sci Rep, 2015, 5